These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 26896825)

  • 1. Postmolar choriocarcinoma: An independent risk factor for chemotherapy resistance in low-risk gestational trophoblastic neoplasia.
    Strohl AE; Lurain JR
    Gynecol Oncol; 2016 May; 141(2):276-280. PubMed ID: 26896825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia.
    Lurain JR; Chapman-Davis E; Hoekstra AV; Schink JC
    J Reprod Med; 2012; 57(7-8):283-7. PubMed ID: 22838241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.
    Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR
    Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
    Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
    Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.
    Braga A; Paiva G; Ghorani E; Freitas F; Velarde LGC; Kaur B; Unsworth N; Lozano-Kuehne J; Dos Santos Esteves APV; Rezende Filho J; Amim J; Aguiar X; Sarwar N; Elias KM; Horowitz NS; Berkowitz RS; Seckl MJ
    Lancet Oncol; 2021 Aug; 22(8):1188-1198. PubMed ID: 34181884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia.
    Maestá I; Growdon WB; Goldstein DP; Bernstein MR; Horowitz NS; Rudge MV; Berkowitz RS
    Gynecol Oncol; 2013 Aug; 130(2):312-6. PubMed ID: 23707672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
    Braga A; Biscaro A; do Amaral Giordani JM; Viggiano M; Elias KM; Berkowitz RS; Seckl MJ
    Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():50-55. PubMed ID: 29477553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom.
    Taylor F; Short D; Winter MC; Tidy J; Savage PM; Sarwar N; Hancock BW; Seckl MJ; Coleman RE
    Gynecol Oncol; 2015 Feb; 136(2):258-63. PubMed ID: 25542400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for methotrexate resistance in low-risk gestational trophoblastic neoplasia patients (FIGO score 0-4).
    Jin T; Zhou Z; Lin M; Yuan S; Xue Y; Yin T; Xu R; Chen B; Zhang J; Sun J; Li X; Hu Y; Chen L; Wang H
    Am J Cancer Res; 2024; 14(3):1353-1362. PubMed ID: 38590416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma?
    Braga A; Campos V; Filho JR; Lin LH; Sun SY; de Souza CB; da Silva RCAF; Leal EAS; Silveira E; Maestá I; Madi JM; Uberti EH; Viggiano M; Elias KM; Horowitz N; Berkowitz RS
    Gynecol Oncol; 2018 Feb; 148(2):239-246. PubMed ID: 29248195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia.
    Li L; Wan X; Feng F; Ren T; Yang J; Zhao J; Jiang F; Xiang Y
    BMC Cancer; 2018 May; 18(1):585. PubMed ID: 29792175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of hydatidiform mole follow-up setting on postmolar gestational trophoblastic neoplasia outcomes: a cohort study.
    Dantas PR; Maestá I; Cortés-Charry R; Growdon WB; Braga A; Rudge MV; Berkowitz RS
    J Reprod Med; 2012; 57(7-8):305-9. PubMed ID: 22838246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gestational trophoblastic neoplasia: treatment outcomes from a single institutional experience.
    Al-Husaini H; Soudy H; Darwish A; Ahmed M; Eltigani A; Edesa W; Elhassan T; Omar A; Elghamry W; Al-Hashem H; Al-Hayli S; Madkhali I; Ahmad S; Al-Badawi IA
    Clin Transl Oncol; 2015 May; 17(5):409-15. PubMed ID: 25398721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of extremely high risk and resistant gestational trophoblastic neoplasia patients in King Chulalongkorn Memorial Hospital.
    Oranratanaphan S; Lertkhachonsuk R
    Asian Pac J Cancer Prev; 2014; 15(2):925-8. PubMed ID: 24568520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.
    Braga A; Maestá I; Matos M; Elias KM; Rizzo J; Viggiano MG
    Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics of Gestational Trophoblastic Neoplasia: A 15-Year Hospital-Based Study.
    Sun R; Zhang Y; Zheng W; Tian Q; An R; Xue Y
    Int J Gynecol Cancer; 2016 Jan; 26(1):216-21. PubMed ID: 26512786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia.
    Maestá I; Nitecki R; Desmarais CCF; Horowitz NS; Goldstein DP; Elias KM; Berkowitz RS
    Gynecol Oncol; 2020 May; 157(2):372-378. PubMed ID: 32037196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gestational trophoblastic neoplasia after achieving a nondetectable serum human chorionic gonadotrophin level.
    Gueye M; Kane-Gueye SM; Ndiaye-Gueye MD; Mbaye M; Diouf AA; Niang MM; Diallo M; Moreau JC
    BJOG; 2014 Oct; 121(11):1415-9. PubMed ID: 24674295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasia.
    Maestá I; Berkowitz RS; Goldstein DP; Bernstein MR; Ramírez LA; Horowitz NS
    Gynecol Oncol; 2015 Jul; 138(1):50-4. PubMed ID: 25933681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
    Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
    Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.